Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
HemaSphere · 2024-07 · 8 (7)
DOI: 10.1002/hem3.136 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 24.07.2024. Verfasst von Michael H Tomasson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine University of Iowa Iowa City Iowa USA. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Internal Medicine University of Iowa Iowa City Iowa USA.
- Department of Hematology & Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.
- Multiple Myeloma Center New York-Presbyterian Hospital/Weill Cornell Medical Center New York New York USA.
- Hematology and Cellular Therapy Department Sorbonne University, Hôpital Saint-Antoine and INSERM UMRS938 Paris France.
- Division of Hematology and Bone Marrow Transplantation, Arnie Charbonneau Cancer Institute University of Calgary Calgary Alberta Canada.
- Haematology and Haemotherapy Service Hospital Universitario 12 de Octubre, Complutense University of Madrid, Centro Nacional de Investigaciones Oncológicas, Instituto de Investigación Hospital 12 de Octubre Madrid Spain.
ORCID-Profile: Michael H Tomasson, Paula Rodriguez-Otero
Förderung
- NCI NIH HHS
Zitieren
APA
Tomasson, M. H., Iida, S., Niesvizky, R., Mohty, M., Bahlis, N. J., Martinez-Lopez, J., Koehne, G., Rodriguez-Otero, P., Miles Prince, H., Viqueira, A., Leip, E., Conte, U., Sullivan, S. T., & Lesokhin, A. M. (2024). Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study. HemaSphere, 8(7). https://doi.org/10.1002/hem3.136
Vancouver
Tomasson MH, Iida S, Niesvizky R, Mohty M, Bahlis NJ, Martinez-Lopez J, et al. Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study. HemaSphere. 2024;8(7). doi:10.1002/hem3.136
BibTeX
@article{Tomasson2024,
author = {Tomasson, Michael H and Iida, Shinsuke and Niesvizky, Ruben and Mohty, Mohamad and Bahlis, Nizar J and Martinez-Lopez, Joaquin and Koehne, Guenther and Rodriguez-Otero, Paula and Miles Prince, H and Viqueira, Andrea and Leip, Eric and Conte, Umberto and Sullivan, Sharon T and Lesokhin, Alexander M},
title = {Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study},
journal = {HemaSphere},
year = {2024},
volume = {8},
number = {7},
doi = {10.1002/hem3.136}
}
EUVIMED